Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment

Gianluca Sottilotta; Carmelo Mangano; Rosa Basile; Carmela Falcone; Francesca Luise; Demetrio Megalizzi; Giovanna Maria Nicolò; Vincenzo Oriana; Angela Piromalli

doi:10.1177/2050313X211016991

Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment

SAGE Open Med Case Rep. 2021 May 26:9:2050313X211016991. doi: 10.1177/2050313X211016991. eCollection 2021.

Authors

Gianluca Sottilotta¹, Carmelo Mangano², Rosa Basile², Carmela Falcone³, Francesca Luise⁴, Demetrio Megalizzi¹, Giovanna Maria Nicolò⁵, Vincenzo Oriana¹, Angela Piromalli⁴

Affiliations

¹ Hemophilia Centre, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
² Infectious Disease Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
³ Radiology Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
⁴ Analysis Laboratory, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
⁵ Clinical Pathology, University of Catania, Catania, Italy.

Abstract

Patients with COVID-19 are at high risk of thromboembolic events; for this reason, the use of heparin is largely recommended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hematoma is a very rarely described hemorrhagic complication in patients with COVID-19. We report here two cases of iliopsoas hematoma in male patients with COVID-19 and being treated with heparin.

Keywords: COVID-19; Iliopsoas hematoma; low-molecular-weight heparin.

Publication types

Case Reports